Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,080 INR | +0.87% | +1.92% | +26.51% |
02:12pm | Glenmark Lifesciences' Net Profit Slides in Fiscal Q4 | MT |
Apr. 01 | Glenmark Pharmaceuticals Limited Announces Board Changes | CI |
Sales 2024 * | 121B 1.46B | Sales 2025 * | 140B 1.69B | Capitalization | 302B 3.63B |
---|---|---|---|---|---|
Net income 2024 * | 33.36B 401M | Net income 2025 * | 11.13B 134M | EV / Sales 2024 * | 2.65 x |
Net Debt 2024 * | 19.84B 238M | Net cash position 2025 * | 3.08B 36.98M | EV / Sales 2025 * | 2.13 x |
P/E ratio 2024 * |
42.2
x | P/E ratio 2025 * |
24.8
x | Employees | 15,556 |
Yield 2024 * |
0.22% | Yield 2025 * |
0.26% | Free-Float | 49.03% |
Latest transcript on Glenmark Pharmaceuticals Limited
1 day | +0.87% | ||
1 week | +3.70% | ||
Current month | +12.71% | ||
1 month | +12.86% | ||
3 months | +21.23% | ||
6 months | +43.89% | ||
Current year | +26.51% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | - | |
Chief Executive Officer | 54 | 98-10-11 | |
Ulhas Dhuppad
PSD | President | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 59 | 20-08-13 | |
Cherylann Pinto
BRD | Director/Board Member | 56 | 99-10-05 |
Chief Executive Officer | 54 | 98-10-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 4 M€ | -4.41% | - | |
0.01% | 117 M€ | +0.68% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 1,080 | +0.87% | 1 101 089 |
24-04-24 | 1,071 | +3.52% | 657,378 |
24-04-23 | 1,034 | -0.47% | 1,223,564 |
24-04-22 | 1,039 | +1.26% | 260,452 |
24-04-19 | 1,026 | -1.48% | 762,705 |
Delayed Quote NSE India S.E., April 25, 2024 at 06:29 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+26.51% | 3.63B | |
+20.70% | 42.78B | |
+18.59% | 22.25B | |
+14.78% | 14.39B | |
+12.83% | 13.55B | |
+38.02% | 11.27B | |
-9.80% | 6.95B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+6.29% | 5.01B |
- Stock Market
- Equities
- GLENMARK Stock